PET and SPECT Techniques Combined, Increasing Resolution for Biomedical Imaging Research

It can reveal functional details smaller than half a millimeter.

TU Delft (The Netherlands) and Molecular Imaging Labs (MI Labs; Utrecht, The Netherlands) have succeeded in combining two forms of medical imaging techniques into one piece of equipment. These techniques are particularly useful for cancer research. The two techniques are known as microPET and microSPECT. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) can be performed simultaneously and they give a higher resolution than traditional microSPECT and microPET.

PET and SPECT are used in cancer research and diagnosis applications. PET and SPECT are also typically used to perform essential research into living cells and disease processes or to develop better methods of diagnosis and treatment. The equipment that has now been developed at TU Delft and MI Labs is designed for basic research using experimental animal models. The combined PET/SPECT apparatus offers extremely high resolution, reduces use of laboratory animals, and also offers cost savings when carrying out research in this area. Previously, both types of equipment would have had to be bought separately and less information could be gained from each individual animal.

Prof. Freek Beekman at TU Delft and CEO/CSO of MI Labs, previously was in charge of developing the U-SPECT, one of the two elements in the new combined apparatus. This U-SPECT (ultra-high-resolution single photon emission computed tomography) is much more precise than the normal SPECT apparatus or other scanning techniques. "These scanners allow us to see how cells and organs function in unprecedented detail. There are already more than 10 U-SPECTs around the globe, which can test new tracers and pharmaceuticals for cancer, cardiac problems, and brain diseases,” said Prof. Beekman.

The U-SPECT, and later the combined U-SPECT/PET scanner, is currently being used for research using mice. "The challenge is now to build a U-SPECT that can be used on people, so that tumors can be detected and classified early, for example, and the right treatment can be started immediately,” stated Prof. Beekman.

The further development of U-SPECT is part of the worldwide search for more efficient medical imaging technology, radiotherapy, and tumor seekers. These efforts are slowly but surely leading to ever better cancer treatments, according to Prof. Beekman.

TU Delft and MILabs are taking action in this area by participating in Medical Delta, with the aim to realize breakthroughs in medical sciences and health care, to develop novel technologies and to fuel related economic opportunities. They are cooperating with Erasmus University, the University of Leiden (both in The Netherlands), and their two affiliated academic hospitals.

Related Links:
TU Delft
Molecular Imaging Labs